Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02917421 · ClinicalTrials.gov registry record · Phase 1
Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations
A Phase 1 study of Breast Cancer, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 3
- Study locations
NCT02917421: Active Phase 1 study of Breast Cancer, sponsored by Weill Medical College of Cornell University.
NCT02917421 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 88 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02917421, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 3
- Study locations
Study Summary
This protocol is for patients with newly diagnosed breast cancer with an indication for post-operative radiotherapy after neo-adjuvant chemotherapy and surgery.
Primary Outcome
feasibility of accelerated radiotherapy in the post-operative setting of breast cancer patients treated by neo-adjuvant chemotherapy and surgery will be measured, by evaluating the number of patients who experience grade II-III dermatitis within 60 days of the end of treatment. Acute Toxicity will be graded using CTCAE v4.0.
Conditions Studied
Interventions
- RADIATION Radiation
Study Locations (3)
New York
- New York Presbyterian Hospital - Queens - New York
- Weill Cornell Medical College - New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT02917421 still lists
NCT02917421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation is the first listed.
NCT02917421 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02917421 about?
NCT02917421 is a clinical study titled "Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations". This protocol is for patients with newly diagnosed breast cancer with an indication for post-operative radiotherapy after neo-adjuvant chemotherapy and surgery.
What is the current status of trial NCT02917421?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2016-12-19. Estimated completion is 2026-12-31.
What conditions does trial NCT02917421 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02917421?
The interventions under investigation include: Radiation (RADIATION).
Who is sponsoring clinical trial NCT02917421?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02917421 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02917421's enrollment target sits among peer trials
88 625th of 1224 higher than 598 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI